RE:RE:RE:RE:RE:RE:Any company’s management team has a duty to maximize It's hard to put a price on TLT considering its ACT is so novel & versatile. I don't look at our value per indication, because it's so much more than that. Establishing efficacy across more than a single solid tumor type would be impressive & would dramatically change the approach to this company's valuation...as it becomes more evident that we may be sitting on a silver bullet for solid cancers in the name of TLD-1433 (or its improved version). Then consider the inordinate added value x-ray activation (or its equivalent) would bring. Then imagine if all goes well in the infectious disease dept. By this point, it would be a fool's errand trying to assign a value : )
I hope we can remain independent until "at least" we have FDA approval with NMIBC & proven efficacy in at least one other indication. Good luck..